Lisata Therapeutics, Inc. (LSTA)
NASDAQ: LSTA · Real-Time Price · USD
1.970
-0.060 (-2.96%)
At close: Dec 5, 2025, 4:00 PM EST
2.050
+0.080 (4.06%)
After-hours: Dec 5, 2025, 6:06 PM EST
Lisata Therapeutics Employees
Lisata Therapeutics had 26 employees as of December 31, 2024. The number of employees increased by 1 or 4.00% compared to the previous year.
Employees
26
Change (1Y)
1
Growth (1Y)
4.00%
Revenue / Employee
$41,154
Profits / Employee
-$701,615
Market Cap
17.38M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LSTA News
- 4 weeks ago - Lisata Therapeutics, Inc. (LSTA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year' - GlobeNewsWire
- 4 weeks ago - Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent - GlobeNewsWire
- 5 weeks ago - Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025 - GlobeNewsWire
- 7 weeks ago - Lisata Therapeutics to Present at LD Micro Main Event XIX - Newsfile Corp
- 2 months ago - Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement - GlobeNewsWire
- 2 months ago - Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial - GlobeNewsWire